Anaplastic Thyroid Cancer Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 8+ Companies and 8+ Therapies
DelveInsight's, 'Anaplastic Thyroid Cancer Pipeline Insight 2025,' report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Anaplastic Thyroid Cancer pipeline landscape. It covers the Anaplastic Thyroid Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Anaplastic Thyroid Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the Anaplastic Thyroid Cancer Pipeline. Dive into DelveInsight's comprehensive report today! @ Anaplastic Thyroid Cancer Pipeline Outlook
Key Takeaways from the Anaplastic Thyroid Cancer Pipeline Report
In June 2025, M.D. Anderson Cancer Center announced a phase II trial studies how well autologous tumor infiltrating lymphocytes LN-145 (LN-145) or LN-145-S1 works in treating patients with ovarian cancer, triple negative breast cancer (TNBC), anaplastic thyroid cancer, osteosarcoma, or other bone and soft tissue sarcomas that do not respond to treatment (refractory) or that has come back (relapsed).
DelveInsight's Anaplastic Thyroid Cancer Pipeline report depicts a robust space with 8+ active players working to develop 8+ pipeline therapies for Anaplastic Thyroid Cancer treatment.
The leading Anaplastic Thyroid Cancer Companies such as Takeda, Shanghai Henlius Biotech, Taizhou Hanzhong Pharmaceuticals, AffyImmune Therapeutics, Inc., Merck & Co, Iovance Biotherapeutics, Inc., Codiak BioSciences, Hutchison Medipharma Limited, Bristol-Myers Squibb and others.
Promising Anaplastic Thyroid Cancer Pipeline Therapies such as Pembrolizumab, Lenvatinib, Nivolumab, Sorafenib (Nexavar,BAY43-9006), dabrafenib/trametinib, Sacituzumab govitecan, MLN0128, Pembrolizumab (Keytruda), efatutazone, HLX208 and others.
Stay ahead with the most recent pipeline outlook for Anaplastic Thyroid Cancer. Get insights into clinical trials, emerging therapies, and leading companies with Anaplastic Thyroid Cancer @ Anaplastic Thyroid Cancer Treatment Drugs
Anaplastic Thyroid Cancer Emerging Drugs Profile
Sapanisertib: Takeda
Sapanisertib is a dual TORC 1/2 inhibitor that targets a key survival mechanism in KEAP1/NRF2-mutated tumor cells. These mutations are found in a considerable sub-population of patients across multiple solid tumor types. Sapanisertib has demonstrated promising single-agent activity in patients with relapsed/refractory NRF2-mutated squamous non-small cell lung cancer (NSCLC) and exhibits differential anti-tumor activity compared to rapalog inhibitors of TORC1 in NRF2-mutant squamous NSCLC in vivo models.
HLX208: Shanghai Henlius Biotech
BRAF V600E small-molecule inhibitor can be potentially used in the treatment of various solid tumors. HLX208 may be combined with the Company's proprietary EGFR or PD-1 targeted antibodies to enhance a high-quality, innovative and differentiated product portfolio for the treatment of various cancer types.
The Anaplastic Thyroid Cancer Pipeline Report Provides Insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Anaplastic Thyroid Cancer with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Anaplastic Thyroid Cancer Treatment.
Anaplastic Thyroid Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Anaplastic Thyroid Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Anaplastic Thyroid Cancer market
Explore groundbreaking therapies and clinical trials in the Anaplastic Thyroid Cancer Pipeline. Access DelveInsight's detailed report now! @ New Anaplastic Thyroid Cancer Drugs
Anaplastic Thyroid Cancer Companies
Takeda, Shanghai Henlius Biotech, Taizhou Hanzhong Pharmaceuticals, AffyImmune Therapeutics, Inc., Merck & Co, Iovance Biotherapeutics, Inc., Codiak BioSciences, Hutchison Medipharma Limited, Bristol-Myers Squibb and others.
Anaplastic Thyroid Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Inhalation
Inhalation/Intravenous/Oral
Intranasal
Intravenous
Intravenous/ Subcutaneous
NA
Oral
Oral/intranasal/subcutaneous
Parenteral
Subcutaneous
Anaplastic Thyroid Cancer Products have been categorized under various Molecule types such as
Antibody
Antisense oligonucleotides
Immunotherapy
Monoclonal antibody
Peptides
Protein
Recombinant protein
Small molecule
Stem Cell
Vaccine
Unveil the future of Anaplastic Thyroid Cancer Treatment. Learn about new drugs, Anaplastic Thyroid Cancer Pipeline developments, and key companies with DelveInsight's expert analysis @ Anaplastic Thyroid Cancer Market Drivers and Barriers
Scope of the Anaplastic Thyroid Cancer Pipeline Report
Coverage- Global
Anaplastic Thyroid Cancer Companies- Takeda, Shanghai Henlius Biotech, Taizhou Hanzhong Pharmaceuticals, AffyImmune Therapeutics, Inc., Merck & Co, Iovance Biotherapeutics, Inc., Codiak BioSciences, Hutchison Medipharma Limited, Bristol-Myers Squibb and others.
Anaplastic Thyroid Cancer Pipeline Therapies- Pembrolizumab, Lenvatinib, Nivolumab, Sorafenib (Nexavar, BAY43-9006), dabrafenib/trametinib, Sacituzumab govitecan, MLN0128, Pembrolizumab (Keytruda), efatutazone, HLX208 and others.
Anaplastic Thyroid Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Anaplastic Thyroid Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Anaplastic Thyroid Cancer Pipeline Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Anaplastic Thyroid Cancer Companies, Key Products and Unmet Needs
Table of Contents
Introduction
Executive Summary
Anaplastic Thyroid Cancer: Overview
Pipeline Therapeutics
Therapeutic Assessment
Anaplastic Thyroid Cancer – DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
Drug name: Company name
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Sapanisertib: Takeda
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
AIC100: AffyImmune Therapeutics
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Anaplastic Thyroid Cancer Key Companies
Anaplastic Thyroid Cancer Key Products
Anaplastic Thyroid Cancer- Unmet Needs
Anaplastic Thyroid Cancer- Market Drivers and Barriers
Anaplastic Thyroid Cancer- Future Perspectives and Conclusion
Anaplastic Thyroid Cancer Analyst Views
Anaplastic Thyroid Cancer Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/anaplastic-thyroid-cancer-pipeline-insight
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
Tesla Inc: Analyst Update & Stock Analysis
Tesla Inc. (TSLA) (About (STA Research): Is a Canadian investment research company, consisting of Financial Professionals specializing in advanced stock research and analysis). Coverage Update Cantor Fitzgerald analyst, Andres Sheppard has reiterated the investment firm's 'Overweight' rating on Tesla Inc., maintaining a 12-month price target of $355.00. This reaffirmation reflects continued confidence in Tesla's long-term growth potential, driven by its leadership in the electric vehicle (EV) sector, ongoing advancements in battery technology, and expanding global production capacity. The Overweight rating suggests that Cantor believes Tesla shares are poised to outperform the broader market or sector average. The price target implies a substantial upside from current trading levels, signaling optimism around the company's ability to scale operations, improve margins, and capitalize on the accelerating global transition to clean energy transportation. Stock Forecast & Analysis As of June 17, 2025, Tesla is trading at $329.13, reflecting a 1.17% increase from the previous close. The stock has experienced a 37% rally since late April, bolstered by investor optimism surrounding Tesla's advancements in artificial intelligence and autonomous vehicle technology, particularly the anticipated launch of its robotaxi service in Austin, Texas, on June 22 Analyst sentiment on Tesla remains mixed, as the consensus rating is 'Hold,' with an average 12-month price target of $289, suggesting a potential downside of approximately 12% from the current trading price . The basis for the cautious approch, is that some analysts have concerns over regulatory issues and increased competition in the electric vehicle market sector. Financial Fundamentals Tesla has exhibited strong revenue growth over the past five years, with a compound annual growth rate (CAGR) of approximately 30%. While its gross margin has compressed to around 17–18% due to pricing cuts and higher input costs (down from previous highs above 25%), the company maintains solid profitability. Operating margins range between 9% and 11%, and net profit margins are approximately 7–10%, which are higher than those of most traditional automakers. Tesla's return on equity (ROE) is strong at around 18–20%, and return on assets (ROA) stands at about 10–12%. From a liquidity standpoint, Tesla is in a healthy position, with a current ratio of roughly 1.5× and a low debt-to-equity ratio of about 0.10×, indicating minimal reliance on leverage. Its interest coverage ratio is well above 20×, reflecting strong ability to meet its financial obligations. The company holds more than $25 billion in cash, providing ample operational and strategic flexibility. Tesla also generates solid free cash flow, currently estimated at $8–10 billion on a trailing 12-month basis. Capital expenditures are rising, reflecting continued investments in artificial intelligence infrastructure and new gigafactories. Its operating cash flow remains consistently positive and supports its growth plans. In terms of valuation, Tesla trades at a forward price-to-earnings (P/E) ratio of around 75× (2025 estimates), significantly higher than the auto industry average. Its EV/EBITDA multiple is also elevated, and the PEG ratio exceeds 2.0×, indicating that the stock is priced at a premium relative to its expected earnings growth. Outlook Tesla Inc. operates in the electric vehicle (EV), energy storage, and AI-powered autonomous technology sectors. It is widely recognized not only as a car manufacturer but also as a technology and energy innovation company. The company's strong brand, vertically integrated business model, extensive charging infrastructure, and first-mover advantage in self-driving technology have helped it establish a significant competitive edge. However, Tesla faces several structural and execution risks, including rising competition from legacy automakers and EV-focused companies such as BYD, Ford, and Volkswagen, as well as increased regulatory scrutiny and heavy reliance on the leadership and public perception of CEO Elon Musk. However, looking at the company's overall picture, Tesla shows robust financial health, strong margins, and efficient capital management, though its current valuation reflects high investor expectations for continued innovation and long-term growth, however the valuation is purely based on the basis that the company is actually a Artifical Intelligence play, according to Ark's Cathy Woods.
National Post
2 hours ago
- National Post
Prodapt Announces Agentic Solutions for Autonomous Operations Powered by NVIDIA AI Platform
Article content Working with human experts, AI Agents simplify & automate operations, elevate experiences Article content CHENNAI, India — Prodapt, a Gartner-recognized Telecom-Native services and AI integration leader, today announced a new Agentic AI based solution to drive autonomous operations for Telcos, in collaboration with NVIDIA. Article content The solution leverages the NVIDIA AI platform to build and deploy Telco-trained AI Agents that predict, analyze, reason, and simulate to resolve incidents impacting service quality and customer experience. Article content Telcos want to deliver better experiences and cut costs and AI Agents help by accelerating the next transformational leap from traditional BSS/OSS systems. This requires agile AI infrastructure, cutting-edge GenAI platforms, and AI integration skills, to enable scalability as the industry evolves beyond experimentation. As part of its Practical AI strategy, Prodapt has built a range of AI Agents across the Telecom value chain, which are powered by NVIDIA NIM™ and NVIDIA NeMo™ microservices. These agents go beyond simple actions, solving multi-step problem statements to improve operational efficiency, customer experience, revenue monetization, enterprise modernization, and accelerate the deployment of critical applications. Article content Autonomous Operations (AO) Article content The first Autonomous Agent is focused on Network operations: Article content The Telecom network issue resolution workflow is complex – impaired by a legacy stack and inability to forecast issues or ascertain available field resources in last-mile service delivery. Prodapt's solution inserts AI Agents across this workflow, deploying them for predictive analytics, issuing proactive alerts, finding the right Network Engineer and dispatching jobs, creating issue summaries, enabling guided resolution plans, and closing the loop after resolution. Simulations suggest the solution will enable Telcos to achieve a 30% improvement in resolution cycle time and drive better resource utilization. Article content 'Prodapt's AO solution developed with NVIDIA AI Enterprise is compelling for two reasons: it combines AI agents and human expertise in the most ingenious way possible, and secondly, it future-proofs Telco networks, going from reactive to proactive operations by mainstreaming Agentic AI into the full lifecycle,' said Chris Penrose, Global Head of Business Development, Telecoms, at NVIDIA. Article content 'AI integration is turning out to be the Number One priority for the Autonomous Operations vision. With a variety of ready to use AI Agents and infrastructure providers crowding a contested market, Telcos need a guiding hand to help them provision and operate the right solutions, operated by handpicked global AI talent. Prodapt delivers what is necessary to turn PoCs into impactful solutions through our Practical AI vision with NVIDIA,' Rajiv Papneja, CTO, Prodapt. Article content About Prodapt Article content Prodapt is the largest specialized player in the Connectedness industry. As an AI-first strategic technology partner, Prodapt provides consulting, business reengineering, and managed services for the largest telecom and tech enterprises building networks and digital experiences of tomorrow. A ServiceNow-invested company, Prodapt has been recognized by Gartner as a Large, Telecom-Native, Regional IT Service Provider. Article content Connecting 1.1 billion people and 5.4 billion devices across the globe, Prodapt's clients include Google, Amazon, PayPal, SoftBank, ServiceNow, Ciena, Verizon, Vodafone, Liberty Global, Liberty Latin America, Claro, Lumen, Windstream, Rogers, Telus, KPN, Virgin Media, British Telecom, Deutsche Telekom, Adtran, Samsung, and many more. Article content A 'Great Place To Work ® Certified™' company, Prodapt employs over 6,000 technology and domain experts across the Americas, Europe, India, Africa, & Japan. Prodapt is part of the 130-year-old business conglomerate The Jhaver Group, which employs over 32,000 people across 80+ locations globally. Article content Article content Article content Article content Article content Article content
CTV News
3 hours ago
- CTV News
CTV National News: How realistic is a 30-day deadline for a trade deal with Canada?
Watch Vassy Kapelos explains why U.S. and Canadian officials believe a 30-day timeline for a bilateral trade deal is realistic.
